LUCIDITY Trial Completes, Topline Avexitide Data Due Within Weeks
AMLX has more than doubled off its 52-week low of $7.48.
Summary
Amylyx completed the 16-week double-blind LUCIDITY trial for avexitide in 78 PBH patients, with topline results expected late August to early September 2026. This is the first report of trial completion, a major catalyst for the stock. Separately, peer-reviewed HELIOS Phase 2 data for AMX0035 in Wolfram syndrome showed Week 96 stabilization and favorable safety, supporting an FDA Phase 3 plan. Q2 adjusted loss improved to $0.39 from $0.46 a year ago, though revenue remains zero. Cash of $250.8M provides runway into 2028. The stock has rallied 80.9% YTD, with analyst targets near $23. The upcoming LUCIDITY readout will determine whether avexitide advances toward registration.
At the time of this announcement, AMLX was trading at $23.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $7.48 to $24.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.